Founded by four Brazilian PhD scientists in 2016, OneSkin has emerged as a leader in the skin longevity space, pioneering science-driven topical treatments. The brand’s innovative approach has led to the development of its patented peptide, OS-01, which is the first scientifically proven peptide capable of reversing skin’s biological age. OS-01 works by preventing the accumulation of senescent cells, a primary cause of aging, resulting in skin that looks and functions younger and healthier.
The company is now set to enter an exciting new phase of growth and innovation in skin health, thanks to an oversubscribed Series A funding round led by Selva Ventures. Additional investors include PLUS Capital, Unilever Ventures, Able Partners, SOSV, and Meta Planet, along with prominent individuals such as Brazilian-American model Camila Alves McConaughey and tech entrepreneur Kevin Rose.
OneSkin Secures $20M in Series A Funding to Advance Skin Longevity Research.
“At OneSkin, we are excited to announce this new round of funding, which will further drive our mission to transform how we think about our skin, not only by optimizing our aesthetics using cutting-edge science, but also focusing on its functional role as our largest organ and the impact in our overall health and longevity,” said Carolina Oliveira, Co-Founder and CEO. “This investment will allow us to deepen our commitment to be the best in class in delivering efficacious peptides to modulate aging at the cellular level, ensuring that our science-backed solutions deliver measurable results in promoting healthier skin. We are dedicated to advancing the future of skin health with the most advanced longevity research and innovation,” shared Dr. Alessandra Zonari, Co-Founder and CSO of OneSkin.
The funding will drive accelerated research and the creation of novel formulas, allowing OneSkin to expand its longevity solutions and redefine the future of the anti-aging skincare industry. Resources will also support increased human capital, enabling the company to explore new growth opportunities and sales channels, making its advanced technologies more accessible to a wider audience.
Investor Camila Alves McConaughey, who is passionate about the brand’s mission to redefine aging and improve skin function, shared her excitement about the investment. “As a Brazilian woman, I am thrilled to invest in a brand founded by four Brazilian female scientists – my heritage is something I’m incredibly proud of, and I am honored to support those who are executing this work. The OneSkin team has built a line of products that hold a unique space in the massive skincare market. I fell in love with the products the moment I saw the results on myself, and I knew I had to be a part of it! I’m so looking forward to seeing their future innovations and continued success with the help of this funding.”
“After working with the OneSkin team over the past two years, we are thrilled to deepen our partnership by leading their Series A round. This is our firm’s largest investment, reflecting our high conviction in the company and the team, led by Carolina and Alessandra,” said Madeline Kaplan, partner at Selva Ventures. “We are seeing the beauty and wellness spaces converge as more consumers want efficacious products that make them look and feel their best. OneSkin is well-positioned at the intersection of beauty and wellness, delivering exceptional results that improve both skin appearance and skin health.”
In addition to support from industry investors, OneSkin has attracted recognition for its scientific breakthroughs. Recently named one of Fast Company’s Most Innovative Companies of 2024, the brand has garnered a loyal following among high-profile users, including Alana Hadid, Georgia May Jagger, and Katy Perry. Additionally, longevity advocates such as Dr. David Sinclair, Tony Robbins, and Peter Diamandis have taken notice of OneSkin’s innovative approach to skin health.
